Videos

Fouad Atouf, senior vice president of global biologics at US Pharmacopeia, discusses the importance of robust quality standards in addressing concerns regarding biosimilar safety and efficacy.

Anthony Perissinotti, PharmD, BCOP, provides an overview of the REMS program requirements for bispecific antibodies and describes the processes, procedures, and training programs implemented at his institution.

Diabetes self-management education works with patients own goals to manage the condition, prevent cardiovascular risk, and stay safe.

Experts provide practical guidelines and key takeaways for health care professionals and policymakers on the implementation of bispecific antibodies in DLBCL (diffuse large B cell lymphoma), emphasizing safety, efficacy, and operational strategies.

A panel of experts examines unmet needs in the adoption of bispecific antibody therapy, emphasizing the importance of access and education for diverse stakeholders in oncology care to improve patient outcomes.

The pharmacy director of Baptist Health South Florida details the features and successes of medication delivery services they provide.

Experts discuss opioid use with a focus on validated assessment tools, monitoring strategies, and risk mitigation practices, delving into the complexities of pain scales and emphasizing the need for functional assessments.

Health care professionals discuss navigating challenges in opioid management, emphasizing a patient-centric approach, and address barriers and differences among opioid misuse, abuse, and use disorder.

Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.

Gabriel Hinojosa, PharmD, BCOP, looks beyond frontline regimens in multiple myeloma, and discusses treatment options, adverse events, and complexities in sequencing therapies.

Tune into this special episode of "Public Health Matters" to gain insights into the multifaceted role of pharmacists in public health and HIV care, while also highlighting the personal journey and passions of Alsean Bryant.

The diabetes/weight loss drug has surged in popularity, and new trials are evaluating it for certain pediatric patients.

The diabetes/weight loss drug is be evaluated in trials for pediatric patients who are at least 10 years of age.

Experts discuss strategies to reduce treatment-related toxicities in bispecific antibody treatments, emphasizing clarity on dosing, hydration, and safety concerns.

Robert Mancini, PharmD, reviews pharmacists’ pivotal role in operationalizing use of bispecifics in diffuse large B-cell lymphoma (DLBCL), overcoming challenges, and supporting direct patient care teams.

A growing number of adult and pediatric patients are being diagnosed with type 2 diabetes, despite increases in care modalities.

A panel of experts share insights on overcoming challenges in responsible opioid prescribing and explore emotional responses, aversion to change, and the role of interdisciplinary collaboration in addressing the opioid crisis.

Stephanie Abel, PharmD, BCPS, and Megan Mitchell, PharmD, MS, discuss pharmacist roles in combating biases, fostering collaboration with prescribers, and implementing strategies for effective opioid stewardship.

Kristen Peterson, PharmD, BCOP, explores how pharmacists deliver comprehensive education, empower patients, manage adverse effects, and prioritize outcomes for multiple myeloma care, ensuring quality treatment understanding and adherence.

Pharmacists discuss emerging therapies, challenges, and pharmacists’ vital role in myelofibrosis patient care, emphasizing disease-modifying agents and care team collaboration.

Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration.

Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management.

Two directors of outpatient services at Allegheny Health Network highlight the significance of Meds-to-Beds in promoting medication adherence while improving patient experience.

Providers can consider the patient’s medication history, comorbidities, or migraine type to help choose a first line treatment or refer the patient to specialized care.

Experts describe considerations for selecting appropriate patients for treatment with a bispecific antibody, including prior therapies for relapsed or refractory multiple myeloma. Strategies to quickly prepare patients for treatment with a bispecific antibody are also discussed.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the multifaceted role of oncology pharmacists in diverse care settings, emphasizing their collaboration in treatment decisions and adaption in the evolving landscape of cancer care.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Amir Ali, PharmD, BCOP, FHOPA, delve into bispecific antibody treatments, focusing on strategies for patient safety and optimizing care in the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.

Robert Mancini, PharmD, discusses bispecific therapy advancements and strategies to manage adverse effects in diffuse large B-cell lymphoma (DLBCL) care, offering insights on toxicity phases, monitoring, and patient care.

Jennifer Marsh, PharmD, BCCCP, discusses the current standard of care for hepatic encephalopathy, highlighting challenges in treatment, prescription drug coverage, transition of care, and outpatient treatment access.

Gabriella Farkas, MD PhD, addresses the multifaceted role of pharmacists in the mental health and wellness space